Search Results

Press Releases

MIP Discovery rebrands as Tozaro as it completes transition to supporting cell and gene therapy viral vector analytics and purification

Tozaro’s rationally designed smart polymer affinity reagents offer novel analytics and purification solutions to enhance the development and manufacture of viral vectors in cell and gene therapy Rebrand follows Series A funding round in February 2024

August 5, 2024

·

2 min read

Concept of application new technology in future medicine

IN PARTNERSHIP WITH TOZARO

The Future of Cell and Gene Therapy: Navigating Innovation, Regulation, and Manufacturing Challenges

An interview with Philip Vanek, chief commercialization officer of the International Society for Cell & Gene Therapy (ISCT), reveals both promising developments and significant concerns shaping the advanced therapies sector’s trajectory through 2025 and beyond. This interview was conducted with support from Tozaro.

August 11, 2025

·

8 min read

·

BioSpace Insights

Press Releases

Tozaro closes £7M Series A financing to drive commercialization in cell and gene therapy space

MIP Discovery, an innovative developer of non-biological affinity reagents designed to accelerate the development and production of cell and gene therapies, announced it has closed a £7 million GBP Series A financing round, led by Mercia Ventures.

February 20, 2024

·

3 min read

Tozaro

Tozaro is developing a novel suite of reagents to support development and manufacture of viral vectors in cell and gene therapy. We see viral vectors through a different lens that allows us to approach common applications such as quantification of viral titer or capture chromatography in a completely different way. We believe the industry needs better tools to help realize the potential of cell and gene therapy.